



Universiteit
Leiden
The Netherlands

Safety and immunogenicity of intradermal fractional dose administration of the mRNA-1273 vaccine: a proof-of-concept study

Roozen, G.V.T.; Prins, M.L.M.; Binnendijk, R. van; Hartog, G. den; Kuiper, V.P.; Prins, C.; ... ; Roukens, A.H.E.

Citation

Roozen, G. V. T., Prins, M. L. M., Binnendijk, R. van, Hartog, G. den, Kuiper, V. P., Prins, C., ... Roukens, A. H. E. (2022). Safety and immunogenicity of intradermal fractional dose administration of the mRNA-1273 vaccine: a proof-of-concept study. *Annals Of Internal Medicine*, 175(12), 1771-1774. doi:10.7326/M22-2089

Version: Publisher's Version
License: [Leiden University Non-exclusive license](#)
Downloaded from: <https://hdl.handle.net/1887/3514839>

Note: To cite this publication please use the final published version (if applicable).

Safety and Immunogenicity of Intradermal Fractional Dose Administration of the mRNA-1273 Vaccine: A Proof-of-Concept Study

Background: There is an urgent need for fair and equitable access to safe and effective COVID-19 vaccines. Intradermal (ID) delivery is a dose-sparing technique that can be used to immunize more people with the same limited vaccine stockpile (1). The papillary dermis contains a higher density of antigen-presenting cells than muscle tissue; therefore, ID delivery of a fractional vaccine dose into this skin layer can be as effective as intramuscular (IM) administration of the standard dose (2).

Objective: To assess the safety, tolerability, and immunogenicity of ID fractional dose administration of the mRNA-1273 (Moderna) vaccine as a potential dose-sparing strategy.

Methods and Findings: We conducted a proof-of-concept, dose-escalation, open-label, randomized controlled trial in a tertiary medical center in Leiden, the Netherlands. Participants were recruited in April and May 2021 from a database of people who had previously shown interest in participating in upcoming COVID-19 vaccine trials. Eligible participants were healthy adults aged 18 to 30 years with no history of COVID-19. At every visit, participants were screened for past SARS-CoV-2 infection via serologic testing and polymerase chain reaction and were excluded from further participation if results were positive.

In part one, 10 participants received 10 mcg of mRNA-1273 vaccine (0.05 mL [one tenth of the standard dose]) intradermally at days 1 and 29. In part two, 30 participants were randomly assigned in a 1:1 ratio to receive a 20-mcg dose of mRNA-1273 (0.01 mL [one fifth of the standard dose]) either intradermally or intramuscularly at days 1 and 29. All ID vaccinations were administered using a Becton Dickinson U-100 Micro-Fine insulin syringe with an integrated 29G needle.

Diaries were used to collect self-reported local and systemic adverse events for 14 days after every vaccination (Supplement Sections A and B, available at [Annals.org](https://annals.org)). Concentrations of IgG-

and IgA-binding antibodies against SARS-CoV-2 spike S1 and receptor-binding domain (RBD) and virus neutralization titers were measured at day 36, day 43, and month 7 (Figure).

Thirty-eight of 40 participants remained in the study through day 43, and 31 remained through month 7. The main reasons for premature study termination were COVID-19 or receipt of an additional vaccination elsewhere (Supplement Section C, available at [Annals.org](https://annals.org)).

The average wheal sizes after the first and second 10-mcg ID vaccinations were 8 mm (SD, 1) and 7 mm (SD, 1), respectively. For the 20-mcg dose, the average wheal sizes were 8 mm (SD, 1) and 10 mm (SD, 1), respectively, for the first and second vaccinations.

No serious adverse events occurred. The most commonly reported adverse events were short-lasting and consisted of mild pain, itching, erythema, and swelling at the injection site (Table; Supplement Sections E and F, available at [Annals.org](https://annals.org)). One participant in the 20-mcg ID group reported severe erythema of more than 10 cm in diameter and moderate swelling. This lasted 6 days and was self-limiting and well tolerated (Supplement Section G, available at [Annals.org](https://annals.org)).

All participants showed robust antibody responses at day 43 that were still detectable at month 7. The binding antibody responses for anti-S1 IgG, anti-RBD IgG, and neutralizing antibodies showed similar patterns (Figure, A to D; Supplement Sections H and I, available at [Annals.org](https://annals.org)). At day 43, geometric mean concentrations of neutralizing antibody were 1115 IU/mL (95% CI, 669 to 1858 IU/mL) for the 10-mcg group, 1300 IU/mL (CI, 941 to 1796 IU/mL) for the 20-mcg ID group, and 1052 IU/mL (CI, 733 to 1509 IU/mL) for the 20-mcg IM group. The IgA responses were similar between groups, independent of dose or method of administration (Figure, E to G; Supplement Section J, available at [Annals.org](https://annals.org)).

Discussion: Intradermal delivery of a 2-dose regimen of mRNA-1273 vaccine at 10 or 20 mcg was safe, was well tolerated, and induced durable antibody responses.

This study has 2 limitations. First, although the IgG, IgA, and neutralizing antibody concentrations were highest in the 20-mcg ID group, the sample size did not allow demonstration of statistically significant superiority of ID over IM injection. Second, only healthy volunteers aged 18 to 30 years were included, so the findings on safety and immunogenicity may not apply to the general population.

Although true vaccine efficacy depends on several factors, antibody concentrations measured after fractional dose vaccination in our trial are within the ranges that correlated with high levels of protection in the mRNA-1273 phase 3 trial (3). This is especially true for the 20-mcg ID group.

In conclusion, the safety and immunogenicity results from this trial strongly support advancement of the investigation of ID vaccination with the mRNA-1273 vaccine.

Geert V.T. Roozen, MD

Margaretha L.M. Prins, MD

Department of Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands


Rob van Binnendijk, PhD

Gerco den Hartog, PhD

Department of Immune Surveillance, National Institute for Public Health and the Environment, Bilthoven, the Netherlands

Vincent P. Kuiper, MD

Department of Parasitology, Leiden University Medical Center, Leiden, the Netherlands

Figure. Serum anti-SARS-CoV-2 antibody concentrations.

Each symbol represents a sample from an individual participant at a certain time point. Error bars represent geometric mean concentrations with 95% CIs. anti-N = anti-nucleocapsid; anti-RBD = anti-receptor-binding domain; anti-S1 = anti-spike S1; AU = arbitrary unit; BAU = binding antibody unit; ID = intradermal; IM = intramuscular; LLoQ = lower limit of quantitation; NF₅₀ = neutralizing factor at 50% normalized against an international reference serum. A, B, and C. Anti-SARS-CoV-2 serum IgG concentrations for anti-S1 (A), anti-RBD (B), and anti-N (C), assessed by bead-based immunoassay and reported in BAUs per milliliter. Data at day 1 (before receipt of the first vaccination), day 29 (before receipt of the second vaccination), day 36 (1 week after receipt of the second vaccination), day 43 (2 weeks after receipt of the second vaccination), and month 7 (half a year after receipt of the second vaccination) are reported for the 10-mcg ID dose, the 20-mcg ID dose, and the 20-mcg IM dose. Horizontal dashed lines represent the cutoff for seropositivity (10 BAU/mL for anti-S1, 30 BAU/mL for anti-RBD, and 14 BAU/mL for anti-N). D. Wild-type SARS-CoV-2 (Wuhan strain) microneutralization assay. NF₅₀ is reported in international units per milliliter. The conversion rate from titer to international units was 1/4.064. The horizontal dashed line represents the LLoQ at 15 IU/mL (titer of 62). Values with an NF₅₀ below the LLoQ were set to 2 IU/mL (titer of 10). Values above the upper limit of quantitation ($n = 2$ in the 20-mcg ID group and 1 in the 20-mcg IM group at day 43) were set to 2953 IU/mL (titer of 12 000). E, F, and G. Anti-SARS-CoV-2 serum IgA concentrations for anti-S1 (E), anti-RBD (F), and anti-N (G), assessed by bead-based immunoassay and reported in AUs per milliliter. Data at days 1, 29, 36, and 43 are reported for the 10-mcg ID dose, the 20-mcg ID dose, and the 20-mcg IM dose.

Table. Local and Systemic Adverse Events Related to Vaccination*

Event	Vaccination 1			Vaccination 2		
	10 mcg ID (n = 10)	20 mcg ID (n = 15)	20 mcg IM (n = 15)	10 mcg ID (n = 9)	20 mcg ID (n = 15)	20 mcg IM (n = 14)
Local adverse events						
Mild hyperpigmentation	1 (10.0)	2 (13.3)	0 (0.0)	2 (22.2)	1 (6.7)	0 (0.0)
Mild local muscle stiffness	4 (40.0)	4 (26.7)	12 (80.0)	0 (0.0)	6 (40.0)	9 (64.3)
Moderate local muscle stiffness	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (6.7)	0 (0.0)
Mild itching at injection site	2 (20.0)	8 (80.0)	0 (0.0)	3 (33.3)	10 (66.7)	0 (0.0)
Mild pain at injection site	7 (70.0)	11 (73.3)	12 (80.0)	6 (66.7)	11 (73.3)	9 (64.3)
Moderate pain at injection site	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (13.3)	0 (0.0)
Mild swelling	1 (10.0)	5 (33.3)	1 (6.7)	1 (11.1)	2 (13.3)	2 (14.3)
Moderate swelling	0 (0.0)	3 (20.0)	0 (0.0)	0 (0.0)	3 (20.0)	0 (0.0)
Mild erythema	3 (30.0)	10 (60.0)	0 (0.0)	5 (55.6)	3 (20.0)	2 (14.3)
Moderate erythema	0 (0.0)	2 (13.3)	1 (6.7)	0 (0.0)	10 (66.7)	0 (0.0)
Severe erythema	0 (0.0)	1 (6.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Mild axillar lymphadenopathy	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (13.3)	0 (0.0)
Systemic adverse events						
Mild nausea and vomiting	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (6.7)	0 (0.0)
Mild myalgia	0 (0.0)	2 (13.3)	2 (13.3)	0 (0.0)	3 (20.0)	2 (14.3)
Moderate myalgia	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (6.7)	2 (14.3)
Mild headache	0 (0.0)	3 (20.0)	5 (33.3)	0 (0.0)	3 (20.0)	3 (21.4)
Moderate headache	1 (10.0)	1 (6.7)	0 (0.0)	0 (0.0)	2 (13.3)	2 (13.4)
Mild diarrhea	0 (0.0)	0 (0.0)	1 (6.7)	0 (0.0)	0 (0.0)	0 (0.0)
Mild chills	0 (0.0)	1 (6.7)	1 (6.7)	0 (0.0)	1 (6.7)	1 (7.1)
Moderate chills	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (7.1)
Mild fever	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Mild fatigue and malaise	0 (0.0)	5 (20.0)	5 (20.0)	0 (0.0)	5 (20.0)	1 (7.1)
Moderate fatigue and malaise	0 (0.0)	1 (6.7)	0 (0.0)	0 (0.0)	5 (20.0)	3 (21.4)
Mild arthralgia	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Moderate arthralgia	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (7.1)

ID = intradermal; IM = intramuscular.

* Data are numbers (percentages) of participants who experienced the adverse event. All adverse events possibly, probably, or definitely related to the vaccine in the 28 days after administration are reported. Grade 4 (potentially life-threatening) adverse events did not occur.

Corine Prins, BSc

Department of Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands

Jacqueline J. Janse, MSc

Department of Parasitology, Leiden University Medical Center, Leiden, the Netherlands

Annelieke C. Kruithof, PhD

Department of Infectious Diseases, Leiden University Medical Center, and Centre for Human Drug Research, Leiden, the Netherlands

Mariet C.W. Feltkamp, MD, PhD

Department of Medical Microbiology, Leiden University Medical Center, Leiden, the Netherlands

Marjan Kuijer

Department of Immune Surveillance, National Institute for Public Health and the Environment, Bilthoven, the Netherlands

Frits R. Rosendaal, MD, PhD

Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands

Meta Roestenberg, MD, PhD

Department of Infectious Diseases and Department of Parasitology, Leiden University Medical Center, Leiden, the Netherlands

Leo G. Visser, MD, PhD

Anna H.E. Roukens, MD, PhD

Department of Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands

Note: The protocol (available at [Annals.org](https://www.annals.org)) was approved by the Medical Ethical Committee Leiden, Den Haag, Delft (NL 76702.058.21).

Acknowledgment: The authors thank all of the trial participants for their contributions and the members of the data safety monitoring board for their invaluable advice. They also thank all of the people who donated to the crowdfunding that supported the trial. The authors acknowledge the support of CEPI and the participation of Viroclinics for performance of the neutralization assay. Finally, the authors thank the Centre for Human Drug Research for its collaboration and its assistance in the recruitment of participants.

Financial Support: The trial was supported by crowdfunding (Wake Up to Corona) set up by the Leiden University Fund. The funder had no influence on the design or conduct of the trial and did not influence the manuscript.

Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M22-2089.

Data Sharing Statement: The following data and supporting documents will be made available with publication: deidentified participant

LETTERS

data and informed consent form (e-mail, a.h.e.roukens@lumc.nl). These will be made available to researchers whose proposed use of the data has been approved, for any purpose, with a signed data access agreement (restrictions: none).

Corresponding Author: Geert V.T. Roozen, Department of Infectious Diseases C5-P, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, the Netherlands; e-mail, G.V.T.Roozen@lumc.nl.

Previous Posting: This manuscript was posted as a preprint on medRxiv on 28 July 2021. doi:10.1101/2021.07.27.21261116

This article was published at Annals.org on 25 October 2022.

doi:10.7326/M22-2089

References

1. Roozen GVT, Roukens AHE, Roestenberg M. COVID-19 vaccine dose sparing: strategies to improve vaccine equity and pandemic preparedness. *Lancet Glob Health*. 2022;10:e570-e573. [PMID: 35303466] doi:10.1016/S2214-109X(22)00075-4
2. Nicolas JF, Guy B. Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice. *Expert Rev Vaccines*. 2008;7:1201-14. [PMID: 18844594] doi:10.1586/14760584.7.8.1201
3. Gilbert PB, Montefiori DC, McDermott AB, et al. Immune Assays Team. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. *Science*. 2022;375:43-50. [PMID: 34812653] doi:10.1126/science.abm3425